Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report
- 255 Downloads
To report research participants’ baseline characteristics in the AMD2000 study, a prospective, multicenter, 5-year, observational cohort study of Japanese age-related macular degeneration (AMD). The characteristics were determined using multimodal imaging.
Patients with AMD were recruited at 18 clinical sites in Japan between April 2006 and March 2009. Each patient underwent a complete ophthalmic examination, including measurement of best-corrected visual acuity (Landolt chart), indirect ophthalmoscopy, slit-lamp biomicroscopy with a contact lens, optical coherence tomography imaging, fundus photography, and fluorescein and indocyanine green angiography.
Four hundred sixty participants (326 men [70.9%]) were included in the study. At enrollment, 131 eyes (28.5%) had hard drusen and 125 eyes (27.2%) had soft drusen in the macular area. A total of 455 eyes (98.9%) were diagnosed as having wet AMD, and 5 eyes (1.1%), as having dry AMD. Of the 455 eyes with wet AMD, 209 eyes (45.4%) had typical AMD, 228 eyes (49.6%) had polypoidal choroidal vasculopathy (PCV), and 18 eyes (3.9%) had retinal angiomatous proliferation. The size of choroidal neovascularization (CNV) was significantly smaller with indocyanine green angiography than with fluorescein angiography (P < 0.001). Poor baseline visual acuity was associated with cystoid macular edema, older age, scar, extrafoveal macular edema, subfoveal CNV, large branching vascular network, and hard exudates.
Japanese patients with AMD are predominantly male, lack drusen, and have a high rate of PCV.
KeywordsAge-related macular degeneration (AMD) Drusen Multimodal imaging International classification Polypoidal choroidal vasculopathy
We are grateful to all the patients and coinvestigators for their cooperation in the current study. A list of the participating research sites and investigators is given in the Appendix. The authors also thank the following additional investigators at the Translational Research Informatics Center (TRI) at the Foundation for Biomedical Research and Innovation for their contributions to this trial: Ms Emiko Uno for data management; Ms Yasuko Kimura for project management; and Dr Hideaki Kaneda, Dr Shinsuke Kojima, Mr Mikio Yoshidomi, and Dr Atsuhiko Kawamoto for manuscript review.
Conflicts of Interest
A. Tsujikawa, Grant (Alcon, AMO Japan, Bayer, HOYA, Kowa, Novartis, Pfizer, Santen, Senju), Lecture fees (Alcon, AMO Japan, Bayer, Chugai, Kowa, Nidek, Novartis, Pfizer, Santen, Sanwa Kagaku, Senju); Y. Akagi-Kurashige, None; M. Yuzawa, Grant (Alcon Japan, Santen), Consultant fees (Alcon Japan, Astellas Pharma, Janssen Japan), Lecture fees (Astellas Pharma, Bausch & Lomb Japan, Bayer, Japan Focus Company, Novartis, Santen, Senju); T. Ishibashi, None; H. Nakanishi, None; E. Nakatani, None; S. Teramukai, Grant (Daiichi Sankyo), Consultant fee (Daiichi Sankyo, Sanofi, Solasia Pharma, Sysmex, Taiho Pharmaceutical), Lecture fees (Bristol-Myers Squibb, Fujifilm); M. Fukushima, None; N. Yoshimura, None.
- 2.Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration: the International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–74.CrossRefPubMedGoogle Scholar
- 5.Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159(853–60):e1.Google Scholar
- 9.Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–60.CrossRefGoogle Scholar
- 14.Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999;117:1329–45.Google Scholar
- 19.Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy [in Japanese]. Nippon Ganka Gakkai Zasshi. 2005;109:417–27.Google Scholar
- 27.Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, et al. Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. Am J Ophthalmol. 2015;160(85–93):e3.Google Scholar
- 30.Nakata I, Yamashiro K, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study. Am J Ophthalmol. 2013;156(1002–9):e2.Google Scholar